Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Cash & Current Investments (2016 - 2026)

Standard Biotools has reported Cash & Current Investments over the past 16 years, most recently at $187.6 million for Q4 2025.

  • Quarterly Cash & Current Investments fell 35.95% to $187.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $187.6 million through Dec 2025, down 35.95% year-over-year, with the annual reading at $187.6 million for FY2025, 35.95% down from the prior year.
  • Cash & Current Investments was $187.6 million for Q4 2025 at Standard Biotools, down from $194.9 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $463.6 million in Q1 2024 and troughed at $29.5 million in Q4 2021.
  • The 5-year median for Cash & Current Investments is $176.5 million (2022), against an average of $184.0 million.
  • Year-over-year, Cash & Current Investments plummeted 58.66% in 2021 and then soared 565.73% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $29.5 million in 2021, then skyrocketed by 466.05% to $166.8 million in 2022, then tumbled by 30.64% to $115.7 million in 2023, then skyrocketed by 153.15% to $292.9 million in 2024, then plummeted by 35.95% to $187.6 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Cash & Current Investments are $187.6 million (Q4 2025), $194.9 million (Q3 2025), and $237.1 million (Q2 2025).